Pre-diagnostic beta-blocker use and head- and neck cancer risk A nationwide population-based case-control study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Min-Su | - |
dc.contributor.author | Han, Kyung Do | - |
dc.contributor.author | Kwon, Soon Young | - |
dc.date.accessioned | 2021-09-01T14:36:34Z | - |
dc.date.available | 2021-09-01T14:36:34Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-06 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/65265 | - |
dc.description.abstract | beta-blockers have been reported to exhibit potential anticancer effects in various cancer studies. However, few clinical studies concerning head and neck cancer have been conducted. We hypothesized that beta-blockers could decrease the incidence of head and neck cancer. Therefore, we investigated the association between beta-blocker treatment and head and neck cancer incidence. Between January 2006 and December 2015, we selected 12,127 patients with head and neck cancer for this nationwide study using data from the Korean Health Insurance Review and Assessment Service. The patients were matched 1: 5 with 60,635 control participants according to age, sex, and, region. Logistic regression analysis was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) of cancer associated with beta-blocker treatment. In the analysis, a crude (simple), adjusted model (adjusted model for age, sex, income, region of residence, hypertension, diabetes, and hyperlipidemia) was used. The OR for head and neck cancer incidence was not lower in the beta-blocker cohort (OR: 1.18; 95% CI: 1.105-1.26), especially for the oral cavity (OR: 1.165; 95% CI: 1.013-1.340), hypopharynx (OR: 1.555; 95% CI: 1.232-1.963), nasopharynx (OR: 1.251; 95% CI: 1-1.564), and paranasal sinus (OR: 1.378; 95% CI: 1.027-1.849). The duration of beta-blocker use was not related to head and neck cancer incidence. This study did not provide evidence that b-blockers can decrease the risk of head and neck cancer. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | RECURRENCE | - |
dc.subject | PROPRANOLOL | - |
dc.subject | EXPRESSION | - |
dc.subject | PROGNOSIS | - |
dc.subject | SURVIVAL | - |
dc.title | Pre-diagnostic beta-blocker use and head- and neck cancer risk A nationwide population-based case-control study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kwon, Soon Young | - |
dc.identifier.doi | 10.1097/MD.0000000000016047 | - |
dc.identifier.scopusid | 2-s2.0-85068207282 | - |
dc.identifier.wosid | 000480724200058 | - |
dc.identifier.bibliographicCitation | MEDICINE, v.98, no.24 | - |
dc.relation.isPartOf | MEDICINE | - |
dc.citation.title | MEDICINE | - |
dc.citation.volume | 98 | - |
dc.citation.number | 24 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | PROPRANOLOL | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | adrenergic beta-antagonists | - |
dc.subject.keywordAuthor | head and neck neoplasm | - |
dc.subject.keywordAuthor | incidence | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.